Alpha 1 Antitrypsin Deficiency Clinical Trials

A listing of Alpha 1 Antitrypsin Deficiency medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
featured
Alpha-1 Study: A research study for individuals with Alpha-1 Antitrypsin Deficiency

The Alpha-1 Study is a clinical research study currently enrolling individuals 18 to 78 (inclusive) with Alpha-1 Antitrypsin Deficiency.   The purpose of this study is to evaluate

alpha1-proteinase inhibitor (human)
deficiency
alpha 1-antitrypsin
  • 145 views
  • 23 Nov, 2020
  • 7 locations
featured
Role of Genetic Factors in the Pathogenesis of Lung Disease

This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes …

pulmonary fibrosis
pulmonary disease
diabetes
bronchoscopy
  • 120 views
  • 23 Nov, 2020
  • 1 location
Safety Tolerability and Pharmacodynamic Effect of ARO-AAT

with alpha-1 antitrypsin deficiency (AATD).

fibrosis
alpha1-proteinase inhibitor (human)
deficiency
  • 168 views
  • 15 May, 2021
  • 26 locations
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.

The purpose of this study is to investigate the effect of alvelestat (an oral neutrophil elastase inhibitor) on blood and sputum biomarkers in patients with PiZZ, null or rare variant phenotype/genotype alpha-1 anti-trypsin deficient lung disease. Change in a number of different blood and sputum biomarkers related to lung damage, …

alvelestat
deficiency
lung disease
elastase inhibitor
pulmonary disease
  • 355 views
  • 28 Jan, 2021
  • 26 locations
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human) Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 MP doses …

  • 695 views
  • 02 Jun, 2021
  • 71 locations
Role of Genetic Factors in the Development of Lung Disease

This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes …

bronchoscopy
histiocytosis x
pulmonary disease
MRI Scan
lymphangioleiomyomatosis
  • 301 views
  • 02 Jun, 2021
  • 2 locations
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

oral administration of alvelestat (MPH966) in subjects with confirmed AATD defined as PiZZ, PiSZ, Pi*null, or another rare phenotype/genotype known to be associated with either low (serum AAT

COPD
deficiency
emphysema
chronic obstructive pulmonary disease
alpha1-proteinase inhibitor (human)
  • 459 views
  • 02 May, 2021
  • 8 locations
Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients

pulmonary disease (COPD). Therefore, PR is a main component in the management of COPD. In a former study patients with Alpha-1 Antitrypsin deficiency (A1ATD)-related COPD (genotype PiZZ) have been found to

  • 0 views
  • 22 Jan, 2021
  • 1 location
A Study of Belcesiran in Patients With A1ATD-Associated Liver Disease

This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ A1ATD-associated liver

  • 0 views
  • 01 Mar, 2021
  • 1 location
Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD

of adult patients with congenital alpha-1 antitrypsin (AAT) deficiency who have moderate airflow limitation (forced expiratory volume in 1 second 50% [FEV1] 80% of predicted) and FEV1/slow vital

deficiency
forced expiratory volume
lung disease
bronchodilator
pulmonary function test
  • 11 views
  • 23 Jan, 2021
  • 1 location